Strategic Wealth Partners Ltd. lessened its stake in Iqvia Holdings Inc (NYSE:IQV) by 21.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 760 shares of the medical research company’s stock after selling 206 shares during the quarter. Strategic Wealth Partners Ltd.’s holdings in Iqvia were worth $99,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in IQV. Cornerstone Wealth Management LLC purchased a new position in shares of Iqvia in the second quarter worth $176,000. Piedmont Investment Advisors LLC purchased a new position in shares of Iqvia in the second quarter worth $189,000. Aperio Group LLC lifted its holdings in shares of Iqvia by 2.8% in the second quarter. Aperio Group LLC now owns 87,810 shares of the medical research company’s stock worth $8,765,000 after buying an additional 2,358 shares in the last quarter. TD Asset Management Inc. lifted its holdings in shares of Iqvia by 1.7% in the second quarter. TD Asset Management Inc. now owns 129,588 shares of the medical research company’s stock worth $12,936,000 after buying an additional 2,190 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Iqvia in the second quarter worth $2,151,000. 89.33% of the stock is currently owned by hedge funds and other institutional investors.

IQV stock traded down $2.25 during mid-day trading on Friday, reaching $119.60. 15,978 shares of the stock traded hands, compared to its average volume of 1,237,287. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41. Iqvia Holdings Inc has a one year low of $91.57 and a one year high of $135.48. The stock has a market capitalization of $24.64 billion, a price-to-earnings ratio of 27.52, a price-to-earnings-growth ratio of 1.77 and a beta of 0.81.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.03. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The business had revenue of $2.59 billion for the quarter, compared to analysts’ expectations of $2.58 billion. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, equities research analysts expect that Iqvia Holdings Inc will post 5.13 EPS for the current year.

In other Iqvia news, major shareholder Canada Pension Plan Investment sold 3,164,388 shares of the business’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $123.72, for a total transaction of $391,498,083.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Group Holdings (Sbs) Advis Tpg sold 3,573,545 shares of the business’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $123.72, for a total transaction of $442,118,987.40. The disclosure for this sale can be found here. Insiders have sold 7,117,903 shares of company stock worth $881,082,166 in the last quarter. Company insiders own 6.00% of the company’s stock.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Iqvia from a “hold” rating to a “buy” rating and set a $142.00 price target on the stock in a research report on Tuesday, October 23rd. Morgan Stanley boosted their price target on shares of Iqvia from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Monday. Piper Jaffray Companies boosted their price target on shares of Iqvia to $131.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 23rd. Wells Fargo & Co boosted their price target on shares of Iqvia from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Monday, August 13th. Finally, Barclays boosted their price target on shares of Iqvia from $130.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 23rd. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $134.41.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/iqvia-holdings-inc-iqv-shares-sold-by-strategic-wealth-partners-ltd/2667454.html.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Recommended Story: Call Option

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.